No approval for Sputnik V vaccine yet; Drug authority seeks additional data from Dr Reddy’s

An expert panel of India’s central drug authority has sought additional data and information from Dr Reddy’s Laboratories, which has sought emergency use authorisation for Russian Covid-19 vaccine Sputnik V, while deferring its decision on it till the next meeting, sources said.

In light of a February 24 meeting of the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO), the firm presented the interim safety and immunogenicity data of the Gam-Covid-Vac combined vector vaccine generated in the country, along with the interim data from the ongoing Russian study.

According to the sources, the SEC, which deliberated on the EUA application on Thursday, recommended that the firm should present data pertaining to all immunogenicity parameters, unblinded data of serious adverse events and RT-PCR positive cases, along with causality analysis reported till date for further examination.

“It has also asked the Hyderabad-based firm to submit a comparative analysis of the phase 3 immunogenicity data generated on the Indian and Russian studies at various time points. It has also asked the drug-maker to submit the factsheet,” a source said.

“We have had our meeting with the SEC today and will await the feedback from the CDSCO. We will provide an update once we have the feedback,” Dr Reddy’s Laboratories said in a statement.

On February 19, the firm said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for Sputnik V.

In September last year, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod to two COVID-19 vaccines — Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia.

  • Related Posts

    Kerala HC upholds DC’s move against vague discount boards; dismisses chemists’ petitions

    In a landmark judgment, the High Court of Kerala has validated the state Drugs Control Department’s regulatory action targeting deceptive advertising and vague discount boards outside retail pharmacy outlets. The…

    Stakeholders push for stronger supply chain compliance through GSDP training

    In a significant move to strengthen India’s pharmaceutical supply chain and safeguard patient safety, regulators, industry representatives, academia, and the cold chain community have jointly emphasized the urgent need to…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Kerala HC upholds DC’s move against vague discount boards; dismisses chemists’ petitions

    Kerala HC upholds DC’s move against vague discount boards; dismisses chemists’ petitions

    Stakeholders push for stronger supply chain compliance through GSDP training

    Stakeholders push for stronger supply chain compliance through GSDP training

    India’s Battle Against Addiction: From Liquor Ban To ‘Dry Drugs’, Bihar’s Youth Trapped In A Growing Narcotics Crisis

    India’s Battle Against Addiction: From Liquor Ban To ‘Dry Drugs’, Bihar’s Youth Trapped In A Growing Narcotics Crisis

    Ovarian Reserve is ‘Jumping Age’ in Indian Women, SHE Delhi red flags

    Ovarian Reserve is ‘Jumping Age’ in Indian Women, SHE Delhi red flags

    8 Women Develop Complications Post C-Section, 2 Critical

    8 Women Develop Complications Post C-Section, 2 Critical

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control